CALCIMEDICA
CalciMedica was founded in December 2006 by Gonul Velicelebi, Ph.D., Kenneth Stauderman, Ph.D. and Jack Roos, Ph.D., all previously with TorreyPines Therapeutics, where they discovered the role of STIM1 in the Icrac pathway in 2003. Other co-founders, all from the CBR Institute, include Anjana Rao, Ph.D., Patrick Hogan, Ph.D. and Stefan Feske, M.D, who identified Orai1 as the CRAC channel subunit in 2006.
CALCIMEDICA
Industry:
Health Care Information Technology Life Science
Founded:
2006-12-01
Address:
La Jolla, California, United States
Country:
United States
Website Url:
http://www.calcimedica.com
Total Employee:
11+
Status:
Active
Contact:
8589525490
Total Funding:
95.46 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress
Current Advisors List
Board_member
Board_member
Board_member
Board_member
Board_member
Current Employees Featured
Daniel Geffken Interim Chief Financial Officer @ CalciMedica
Interim Chief Financial Officer
2020-11-01
Kenneth A. Stauderman Chief Scientific Officer and Co-Founder @ CalciMedica
Chief Scientific Officer and Co-Founder
2017-04-01
Eric Roberts Chief Business Officer and Vice Chairman of the Board @ CalciMedica
Chief Business Officer and Vice Chairman of the Board
Rachel Leheny Chairman and Chief Executive Officer @ CalciMedica
Chairman and Chief Executive Officer
2019-09-01
Kenneth A. Stauderman Vice President Research @ CalciMedica
Vice President Research
2007-04-01
Michael J. Dunn President and COO @ CalciMedica
President and COO
2016-02-01
Sudarshan Hebbar Chief Medical Officer @ CalciMedica
Chief Medical Officer
2017-04-01
Gonul Velicelebi Founder @ CalciMedica
Founder
2006-10-01
Founder
Investors List
Quark Venture
Quark Venture investment in Series D - CalciMedica
Sanderling Ventures
Sanderling Ventures investment in Series D - CalciMedica
Global health sciences venture fund
Global health sciences venture fund investment in Series D - CalciMedica
Valence Life Sciences
Valence Life Sciences investment in Series D - CalciMedica
Valence Life Sciences
Valence Life Sciences investment in Series C - CalciMedica
Mesa Verde Venture Partners
Mesa Verde Venture Partners investment in Series C - CalciMedica
Bering Capital
Bering Capital investment in Series C - CalciMedica
Sanderling Ventures
Sanderling Ventures investment in Series C - CalciMedica
Sanderling Ventures
Sanderling Ventures investment in Series C - CalciMedica
SR One
SR One investment in Series C - CalciMedica
Official Site Inspections
http://www.calcimedica.com Semrush global rank: 10.21 M Semrush visits lastest month: 25
- Host name: calcimedicadev.tempurl.host
- IP address: 140.82.50.38
- Location: San Jose United States
- Latitude: 37.3387
- Longitude: -121.8914
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 95113
More informations about "CalciMedica"
About Us - CalciMedica
The CalciMedica team is comprised of scientists, physicians, drug development experts and entrepreneurs...See details»
CalciMedica - The Leading CRAC Channel Platform Company
The CalciMedica team is comprised of scientists, physicians, drug development experts and entrepreneurs dedicated to the development of CRAC channel inhibitors for acute and chronic …See details»
Overview | CalciMedica, Inc.
Mar 9, 2023 The Investor Relations website contains information about CalciMedica, Inc.'s business for stockholders, potential investors, and financial analysts.See details»
CalciMedica - LinkedIn
CalciMedica is a privately held, clinical stage biotechnology company with a platform focused on CRAC channel drug discovery and development for the treatment of acute and severe inflammatory ...See details»
CalciMedica - Crunchbase Company Profile & Funding
CalciMedica is engaged in the discovery and development of small molecule drugs for the treatment of inflammatory and autoimmune disorders.See details»
CalciMedica - Leadership Team | The Org
The Leadership Team at CalciMedica is responsible for setting the strategic direction and vision of the company, overseeing all aspects of operations, financial management, and business …See details»
CalciMedica, Inc. - AnnualReports.com
CalciMedica is a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening inflammatory diseases with high unmet need. CalciMedica’s proprietary technology targets the inhibition of CRAC …See details»
CalciMedica, Inc. Company Profile | La Jolla, CA | Competitors ...
Find company research, competitor information, contact details & financial data for CalciMedica, Inc. of La Jolla, CA. Get the latest business insights from Dun & Bradstreet.See details»
Press Releases | CalciMedica, Inc.
The Investor Relations website contains information about CalciMedica, Inc.'s business for stockholders, potential investors, and financial analysts.See details»
CalciMedica - VentureRadar
"CalciMedica is a clinical-stage biopharmaceutical company focused on developing novel CRAC channel inhibition therapies for inflammatory and immunologic diseases. CalciMedica's …See details»
CalciMedica | Startup Profile and Investments - Bounce Watch
CalciMedica is a leader in the development of CRAC channel inhibitor drugs for inflammatory diseases. Founded in 2006 by Ken Stauderman, CalciMedica’s Chief Scientific Officer, and …See details»
CalciMedica (CALC) Company Profile & Description - Stock Analysis
Apr 11, 2025 Company profile for CalciMedica, Inc. (CALC) stock, with a description, list of executives, contact details and other key facts.See details»
CalciMedica, Inc. (CALC) Company Profile & Facts - Yahoo Finance
See the company profile for CalciMedica, Inc. (CALC) including business summary, industry/sector information, number of employees, business summary, corporate governance, …See details»
CalciMedica Announces Presentations at Upcoming Medical …
3 days ago CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium …See details»
CalciMedica - LifeScienceHistory.com
CalciMedicaﾒs lead clinical compound, Auxora, is a potent and selective small molecule inhibitor of Orai1-containing CRAC channels that is being developed for use in patients with acute …See details»
CalciMedica, Inc. (NASDAQ:CALC): A Promising CRAC Channel …
Sep 24, 2024 CalciMedica, Inc. (NASDAQ:CALC) is a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition …See details»
Presentation - CalciMedica, Inc.
The Investor Relations website contains information about CalciMedica, Inc.'s business for stockholders, potential investors, and financial analysts.See details»
CalciMedica, Inc. - Common Stock Stock Overview: CALC Price
About CalciMedica, Inc. - Common Stock (CALC) CalciMedica, Inc. operates as a biopharmaceutical company. It focuses on developing therapies for life-threatening …See details»
CalciMedica Reports 2024 Financial Results and Provides Clinical ...
Mar 27, 2025 About CalciMedica CalciMedica is a clinical-stage biopharmaceutical company focused on developing novel CRAC channel inhibition therapies for inflammatory and …See details»
CalciMedica, Inc. (CALC) - Yahoo Finance
Find the latest CalciMedica, Inc. (CALC) stock quote, history, news and other vital information to help you with your stock trading and investing.See details»